Latest IC/BPS Research, Clinical Trials & Treatment Updates

Updated

ICNetwork.org maintains a dedicated Medical Care, Research & Clinical Trials section that tracks new guidelines, emerging therapies, and drug safety developments for interstitial cystitis/bladder pain syndrome (IC/BPS). If you want to know what has changed recently in diagnosis, phenotyping, or treatment—and where the field is heading—that section is the starting point. Below is a summary of the categories of updates it covers, based on the site's own published headlines and descriptions.

What kinds of updates the site tracks

The section is organized around several recurring themes rather than a single feed:

  • New clinical guidelines — including French IC/BPS guidelines that the site describes as recognizing and expanding upon phenotyping, and new AUA guidelines for male pelvic pain.
  • Emerging treatment modalities — such as pulsed electromagnetic therapy (PEMF), which the site reports is gaining traction in IC clinics.
  • Research linking IC/BPS to other conditions — for example, bladder inflammation and depression, migraines and vulvodynia, prolapse and IC symptoms, and post-UTI hypersensitivity syndrome.
  • Drug safety and legal developments — most prominently a series of updates on Elmiron® (pentosan polysulfate sodium), including reports on retinal disease, maculopathy progression, litigation status, and attorney Q&As.
  • Policy and funding — coverage of how NIH funding cuts affect the field.

Why phenotyping keeps appearing in the updates

A recurring thread across the research and guideline items is phenotyping—grouping patients by the underlying cause or driver of their symptoms. The site's own framing is that "which group you fit into determines your treatments," and it presents phenotype identification as a step between diagnosis and treatment selection. This is why new guidelines that expand phenotyping (like the French guidelines noted above) are treated as significant news rather than routine publication.

Elmiron® updates: what the site covers

The Elmiron®-related items form the largest single cluster of drug-specific updates. According to the site's own headlines and summaries, these include:

Topic What the site reports
Retinal disease Pentosan instillations and injections associated with retinal disease
Maculopathy Elmiron® maculopathy appears to progress
Litigation Millions paid so far; first lawsuit filed (Pelczar v. Teva Branded Pharmaceuticals R&D et al.)
Attorney perspective Q&A with an attorney who has filed more than 50 cases for IC patients with Elmiron eye disease
Investigative history A report on the "tragic and tarnished history" of Elmiron®

If you are currently taking or considering pentosan polysulfate sodium, these updates are the most directly relevant items in the section—but they are news summaries and litigation reports, not medical advice. Discuss any concerns with your prescribing clinician.

How to use this section

  1. Start with the guideline updates if you want to know whether diagnostic or treatment standards have shifted.
  2. Check the phenotyping items if you are trying to understand why your treatment plan differs from another patient's.
  3. Follow the Elmiron® thread if you have a history of pentosan use or are evaluating it as an option.
  4. Use the research-link articles (depression, migraines, prolapse, post-UTI) to see whether any of your other symptoms have been studied in relation to IC/BPS.

The site also offers a free video-based IC101 Master Class for patients, which the homepage describes as a video-driven series for those struggling with IC/BPS.